Oral CorticoSteroid sparing with biologics in severe asthma: A remark of the Severe Asthma Network in Italy (SANI)

Oral CorticoSteroid sparing with biologics in severe asthma: A remark of the Severe Asthma Network in Italy (SANI)

According to the data derived from several national and international registries, including SANI (Severe Asthma Network Italy), and considering the strong impact that frequent or regular use of oral corticosteroid has on quality of life (QoL) of severe asthmatics, as well as on the costs for managin...

Полное описание

Библиографические подробности
Главные авторы:	Giorgio Walter Canonica, Francesco Blasi, Pierluigi Paggiaro, Gianenrico Senna, Giovanni Passalacqua, Antonio Spanevello, Stefano Aliberti, Diego Bagnasco, Marco Bonavia, Matteo Bonini, Luisa Brussino, Caterina Bucca, Maria F. Caiaffa, Cecilia Calabrese, Gianna Camiciottoli, Marco Caminati, Giovanna E. Carpagnano, Cristiano Caruso, Stefano Centanni, Maria E. Conte, Angelo G. Corsico, Lorenzo Cosmi, Maria T. Costantino, Nunzio Crimi, Simona D’Alò, Maria D'Amato, Stefano Del Giacco, Alessandro Farsi, Elisabetta Favero, Maria P. Foschino Barbaro, Gabriella Guarnieri, Giuseppe Guida, Manuela Latorre, Salvatore Lo Cicero, Carlo Lombardi, Luigi Macchia, Francesco Mazza, Francesco Menzella, Manlio Milanese, Marcello Montagni, Paolo Montuschi, Eleonora Nucera, Roberta Parente, Vincenzo Patella, Girolamo Pelaia, Laura Pini, Francesca Puggioni, Luisa Ricciardi, Fabio L.M. Ricciardolo, Luca Richeldi, Erminia Ridolo, Giovanni Rolla, Pierachille Santus, Nicola Scichilone, Giuseppe Spadaro, Andrea Vianello, Vittorio Viviano, Mona R. Yacoub, Maria C. Zappa, Enrico Heffler
Формат:	Статья
Язык:	English
Опубликовано:	Elsevier 2020-10-01
Серии:	World Allergy Organization Journal
Предметы:	Severe asthma Biologics Oral corticosteroids Real-life Registr
Online-ссылка:	http://www.sciencedirect.com/science/article/pii/S1939455120303677

Схожие документы

Patient and physician perspectives on biological treatment in severe asthma: a Severe Asthma Network Italy survey
по: Claudia Crimi, и др.
Опубликовано: (2023-11-01)

Nasal polyps impact in severe asthma patients: evidences from the SANI
по: Giorgio Walter Canonica, и др.
Опубликовано: (2020-08-01)

Economic impact of a more extensive use of FENO testing on the Italian population with asthma
по: Carla Rognoni, и др.
Опубликовано: (2023-06-01)

Asthma severity: the patient’s point of view
по: Gabriella Guarnieri, и др.
Опубликовано: (2024-12-01)

Is Bronchiectasis (BE) Properly Investigated in Patients with Severe Asthma? A Real-Life Report from Eight Italian Centers
по: Giovanna Elisiana Carpagnano, и др.
Опубликовано: (2023-10-01)

Clinical-economic impact of mepolizumab in patients with severe hypereosinophilic asthma
по: Diego Bagnasco, и др.
Опубликовано: (2020-08-01)

Economic impact of mepolizumab in uncontrolled severe eosinophilic asthma, in real life
по: Diego Bagnasco, и др.
Опубликовано: (2021-02-01)

Severe asthma: One disease and multiple definitions
по: Diego Bagnasco, MD, PhD, и др.
Опубликовано: (2021-11-01)

Critical evaluation of asthma biomarkers in clinical practice
по: Giuseppe Guida, и др.
Опубликовано: (2022-10-01)

Biologics in Severe Eosinophilic Asthma: Three-Year Follow-Up in a SANI Single Center
по: Paolo Solidoro, и др.
Опубликовано: (2022-01-01)

Profiling severe asthma: Any relevance for age? An analysis from Severe Asthma Network Italy (SANI) cohort
по: Marco Caminati, MD, и др.
Опубликовано: (2024-08-01)

Phenotype overlap in the natural history of asthma
по: Fabio L.M. Ricciardolo, и др.
Опубликовано: (2023-05-01)

Minimal clinically important difference for asthma endpoints: an expert consensus report
по: Matteo Bonini, и др.
Опубликовано: (2020-06-01)

Long-Term Efficacy of Mepolizumab at 3 Years in Patients with Severe Asthma: Comparison with Clinical Trials and Super Responders
по: Diego Bagnasco, и др.
Опубликовано: (2023-08-01)

Manifesto on the overuse of SABA in the management of asthma: new approaches and new strategies
по: Giorgio Walter Canonica, и др.
Опубликовано: (2021-09-01)

Biologics as well as inhaled anti-asthmatic therapy achieve clinical remission: Evidence from the Severe Asthma Network in Italy (SANI)
по: Giorgio Walter Canonica, MD, и др.
Опубликовано: (2025-01-01)

Tezepelumab: patient selection and place in therapy in severe asthma
по: Francesco Menzella, и др.
Опубликовано: (2024-04-01)

Treatment strategies for asthma: reshaping the concept of asthma management
по: Alberto Papi, и др.
Опубликовано: (2020-08-01)

Omalizumab as add‐on therapy in a patient with severe asthma and OSA
по: Giulia Scioscia, и др.
Опубликовано: (2020-03-01)

Efficacy of Mepolizumab in patients with previous Omalizumab treatment failure: real life observation
по: Diego Bagnasco, и др.
Опубликовано: (2020-08-01)

The evidence on tiotropium bromide in asthma: from the rationale to the bedside
по: Dejan Radovanovic, и др.
Опубликовано: (2017-05-01)

Real-life effects of dupilumab in patients with severe type 2 asthma, according to atopic trait and presence of chronic rhinosinusitis with nasal polyps
по: Corrado Pelaia, и др.
Опубликовано: (2023-03-01)

Vascular remodeling and TSLP/angiogenin overexpression in severe mixed asthma
по: Francesca Bertolini, и др.
Опубликовано: (2025-02-01)

Erratum to: The evidence on tiotropium bromide in asthma: from the rationale to the bedside
по: Dejan Radovanovic, и др.
Опубликовано: (2017-06-01)

Mabs for treating asthma: omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab
по: Erminia Ridolo, и др.
Опубликовано: (2020-10-01)

Brittle asthma
по: O. Toungoussova, и др.
Опубликовано: (2016-02-01)

Long-term effectiveness of benralizumab in severe eosinophilic asthma patients treated for 96-weeks: data from the ANANKE study
по: Alessandra Vultaggio, и др.
Опубликовано: (2023-05-01)

Expression profiling of miRNA-145 and miRNA-338 in serum and sputum of patients with COPD, asthma, and asthma–COPD overlap syndrome phenotype
по: Lacedonia D, и др.
Опубликовано: (2017-06-01)

Clinical and economic consequences of switching from omalizumab to mepolizumab in uncontrolled severe eosinophilic asthma
по: Giovanna Elisiana Carpagnano, и др.
Опубликовано: (2021-03-01)

SANI-Severe Asthma Network in Italy: a way forward to monitor severe asthma
по: G. Senna, и др.
Опубликовано: (2017-04-01)

Benralizumab in Patients With Severe Eosinophilic Asthma With and Without Chronic Rhinosinusitis With Nasal Polyps: An ANANKE Study post-hoc Analysis
по: Maria D'Amato, и др.
Опубликовано: (2022-05-01)

Predictors of reversible airway obstruction with omalizumab in severe asthma: a real-life study
по: Paolo Solidoro, и др.
Опубликовано: (2019-04-01)

The clinical profile of benralizumab in the management of severe eosinophilic asthma
по: Francesco Menzella, и др.
Опубликовано: (2016-12-01)

Positioning tezepelumab for patients with severe asthma: from evidence to unmet needs
по: Carlo Lombardi, и др.
Опубликовано: (2024-11-01)

The extracellular matrix of the lung and airway responsiveness in asthma
по: F.G. Salerno, и др.
Опубликовано: (2016-01-01)

Alexithymia and asthma: a systematic review
по: Orlando Silvestro, и др.
Опубликовано: (2023-08-01)

Very long-term data on patients with severe eosinophilic asthma treated with mepolizumab: a case series
по: Carlo Lombardi, и др.
Опубликовано: (2024-07-01)

“Characteristics of patients admitted to emergency department for asthma attack: a real-LIFE study”
по: Laura Losappio, и др.
Опубликовано: (2019-06-01)

Interleukin-5 in the Pathophysiology of Severe Asthma
по: Corrado Pelaia, и др.
Опубликовано: (2019-12-01)

Role of Leukotrienes and Leukotriene Modifiers in Asthma
по: Paolo Montuschi
Опубликовано: (2010-06-01)